News Conference News ISET 2023 BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions Caitlin E. Cox January 20, 2023
News Conference News Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices L.A. McKeown November 18, 2022
News Conference News VIVA 2021 EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions L.A. McKeown October 12, 2021
News Conference News ISET 2019 Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis Caitlin E. Cox January 30, 2019
News Conference News VIVA 2018 IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions L.A. McKeown November 06, 2018
News Conference News TCT 2018 Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released Todd Neale September 24, 2018
News Conference News TCT 2018 IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease Todd Neale September 22, 2018
News Conference News TCT 2018 TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More Shelley Wood September 17, 2018
News Conference News VIVA 2016 Positive Results Continue at 2 Years for Paclitaxel-Eluting PAD Stent L.A. McKeown September 20, 2016